(19)
(11) EP 4 573 126 A2

(12)

(88) Date of publication A3:
11.04.2024

(43) Date of publication:
25.06.2025 Bulletin 2025/26

(21) Application number: 23769061.5

(22) Date of filing: 18.08.2023
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
A61K 39/00(2006.01)
C07K 14/715(2006.01)
A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/2866; C07K 2317/565; C07K 2317/76; C07K 2317/41; C07K 2317/732; C07K 2317/94; C07K 2317/24; A61P 35/00
(86) International application number:
PCT/US2023/072462
(87) International publication number:
WO 2024/040216 (22.02.2024 Gazette 2024/08)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 19.08.2022 US 202263399483 P

(71) Applicant: Fibrogen, Inc.
San Francisco, California 94133 (US)

(72) Inventors:
  • BROUSSEAU, David T.
    Mill Valley, California 94941 (US)
  • WALKINSHAW, Gail
    San Francisco, California 94158 (US)
  • WITSCHI, Claudia
    San Francisco, California 94158 (US)

(74) Representative: CH Kilger Anwaltspartnerschaft mbB 
Fasanenstraße 29
10719 Berlin
10719 Berlin (DE)

   


(54) ANTI-CCR8 ANTIBODIES AND USES THEREOF